The broader field increasingly recognizes exosomes as regenerative biological particles. NurExone Biologic builds on this foundation in two ways. First, it develops and manufactures naïve exosomes for their intrinsic biological and regenerative properties. Second, it uses proprietary loading technology to add defined therapeutic cargo, converting naïve exosomes into targeted delivery systems without genetically engineering them. For its lead candidate, this means combining the natural cellular-level interactions of exosomes with targeted cargo designed to support neuronal repair. Looking ahead, the company believes the same platform may support the loading of other molecular cargos, expanding the potential of exosomes as natural drug delivery vehicles across multiple indications.